( e indiabetic neuropathic pain. We look...)Avanir Pharmaceuticals Announces Positive Results of Phase III,Study for Zenvia in Diabetic Neuropathic Pain,Health

e in diabetic neuropathic pain. We look forward to the continued development of Zenvia for these two important indications. As previously stated, the company plans on initiating a confirmatory clinical trial in IEED with a new, lower quinidine dose formulation later this year," he added.

Conference Call

The company has scheduled a conference call for today, Wednesday, April 18, 2007 at 10:30 AM ET. Keith Katkin, President and CEO of Avanir, and Randall Kaye, MD, Senior Vice President and Chief Medical Officer, will discuss the results of this Phase III study. The call-in number is (877) 558-3407 for domestic and (706) 679-1941 for international callers, and the conference ID number is 6342812.

If you cannot attend the live broadcast, a webcast will be available online until May 18, 2007 at www.avanir.com. A telephone replay is available until April 23, 2007 and can be accessed by dialing (800) 642-1687 domestic and (706) 645-9291 international, and entering the conference ID number 6342812.

About Diabetic Neuropathic Pain

Diabetic neuropathic pain, one of the most debilitating forms of pain, is caused by nerve damage that can result from diabetes. It is often described as burning, tingling, stabbing, or pins and needles in the feet, legs, hands or arms. An estimated 3.5 million people in the United States experience diabetic neuropathic pain according to the American Diabetes Association.

About the Study

In 2005 AVANIR initiated a randomized double-blind, placebo-controlled, phase III clinical trial testing two doses of Zenvia in patients with painful diabetic neuropathy to assess efficacy, and overall safety and tolerability. The study was conducted at 40 sites in the US and Israel and was fully enrolled with 379 patients randomized across the three treatment arms (45 mg dextromethorphan / 30 mg quinidine BID dose, 30 mg dextromethorphan / 30 mg quinidine BID dose and placebo). The protocol for the study was reviewed
'"/>

Page: 1 2 3 4 5 6
Related medicine technology :

1. Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia Long-Term Safety Data at AAN Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies